T he utilization of chlorprom azine in early 1950's was the beginning of a new era in the treatment of schizophrenia. In the following thirty years nu merous neuroleptics have been launched, most of them having the same fundamental mechanism i.e. the blockade of dopam inergic receptors, but some of their clinical properties were sometimes different inducing a classification based as well upon chem i cal structures as clinical features. The most im por tant problem using these drugs was the dose equ ivalence as compared with chlorpromazine.
While these drugs have shown their efficacy in treating schizophrenia, they induce a wide range of side-effects. Yet psychiatrists tried to use minimal dosages a n d /o r prescribe correctors even if there was not a strong consensus in that practice. On the other hand, classical neuroleptics are more efficient on positive than on negative symptoms, with 25% of patients as responders. Taking care of psychotic patients is an econom ic burden knowing that the epidemiology of schizophrenia comprise between 1 to 27c of the populations anywhere wide world. The global costs were estimated in France around 2.3 billion USD (1) . Drug treatment makes up 5.6% of this cost with only 76% for neuroleptics. An analy sis of lifetime resource use suggests that just 10% of patients incur nearly 80%< of the total lifetime direct costs. These are the patients with episodes lasting more than 2.5 years and who require long-term ca 1 Service de Pharm acologic, Faculte de Medecine de Paris XII, b, rue du General Sarrail, 94010 -Creteil 2 Trofessor of Pharmacology, GIS Medicament, Department of Pharmacology, Faculty of M edicine, B P . 5350S, 4403d Nantes, France re either in hospital or intensive com m unity prog ram. Thus, the failure of conventional therapies to improve the symptoms of a relatively small group of patients substantially increases the total burden of the disease. An im provem ent in treatm ent that halved the size of this group would reduce total li fetime direct costs by 37%> (2) .
The development of new drugs in the field of schizophrenia is orientated towards m olecules ha ving few side effects but as well an effect on negati ve symptoms (3). These new drugs may improve the quality of life of patients, their insertion into so ciety and decrease the indirect costs linked to social burden. Ideally, the therapeutic strategies have to be compared between themselves to optim ize the clinical results and costs.
The dopam inergic hypothesis of Carlsson and Crow, based on the fact that positive symptoms are linked to a hyperactivity of the dopam inergic system, and negative symptoms to a hypoactivity of that system, is now modulated by evidence concer ning other neurotransm itters. Serotonin induces a negative feed back on dopam ine release in some brain areas. Glutam ate inhibits subcortical dopam i nergic activity (4) and a primitive deficit of glutam a te was suggested in schizophrenia. Other neuropep tides such as cholecystokinin and neurotensin are also proposed as m odulators of dopam inergic transmission. The present hypothesis of schizophrenia is ba sed on a dopam inergic transmission deficit in nigrostriatal and m esocortical pathw ays, contrasting with an excess of dopaminergic transmission in m e solimbic area (5) .
The development strategies in this field are not only focused on discovery of specific antagonists of one subtype of dopaminergic receptor (i.e. D3 etc.) but on synthesis of molecules having different ef fects regarding the concerned brain areas.
Antipsychotic drugs with selective blockade of dopaminergic receptors
Up to a few years ago, two dopam inergic recep tor subtypes, D] receptors activating adenylate cyclase and D2 receptors inhibiting adenylate cycla se, were known. Stim ulation Dj receptors leads to an increase in cAMP production whereas, D2 recep tor stim ulation inhibits cAMP production. Now, there are 5 dopam inergic subtypes: D[ and D5 lin ked to a Gs protein; D2 and D4 linked to a Gi prote in; and the D3 receptor, a presynaptic receptor pla ying a role on negative feed back (6) . The dopam i nergic receptor family is wide and there are nume rous studies aimed at discovering selective blockers and agonists of each subtype of receptor and to cor relate the selective binding to a special clinical pro file.
Classical neuroleptics such as haloperidol block m ainh' D2 receptors, whereas benzamides mainly 114 block D2 and D3 receptors (7) .
The D4 receptor is selectively blocked by cloza pine which could explain its better efficacy on ref ractory schizophrenia (8, 9) .
The wide distribution of D2 receptors is an ubi quity expression particularly in neostriatum and hypophysis where its blockade explains motor as well as neuroendocrinological side effects of the conventional neuroleptics. Their blockade at limbic area explains their therapeutic effects on the positi ve symptoms, hallucinations and delusions. Howe ver, they block dopaminergic transm ission in other brain areas, potentially increasing the negative symptoms and leading to tardive dyskinesia.
Blockers of D2 and D3 receptor subtypes
Various research has focused on developm ent of D2 receptor selective blockers with preferential acti ons at mesolimbic level compared to nigro-striatum system. The D3 receptor subtype is located in limbic areas but not in the hypophysis or the striatum.
Benzamide compounds are able to selectively block enough D2 and D3 receptors (10) . For exam p le, sulpiride, preferentially blocks at low dosages presynaptic D3 receptors, giving it a bipolar activity. Clinical trials have shown that sulpiride is an effici ent antipsychotic, yet its side effect profile, particu larly the extra-pyramidal sym ptom s and hyperpro lactinemia, are not correlated with predictions ba sed on dopaminergic selectivity at D2 receptors (11) . A possible explanation is that sulpiride is an hydrophilic drug so it does not easily cross the blo od brain barrier. So, it is necessary to use high doses like 600 to 800 mg per day, and even up to 1 g which induce side effects.
Remoxipride is a weak D2 blocker, but specific for the extrastriatal receptors. On the contrary of typical neuroleptics like haloperidol, animal studies in rats showed that there were wide differences bet ween the doses of rem oxipride in decreasing the lo comotor activity induced by dopam inergic agonists and those inducing catalepsia. In vivo binding stu dies with D2 receptors have shown, that rem oxipri de inhibits the binding of trotted spiperidone in so me limbic areas more than in the striatum , com pa red to typical neuroleptics, which affect identically these two brain areas. Clinical extrapolation from its psychopharmacological profile seems to indicate that remoxiprid? can induce less extrapyram idal ef fects as well as lower prolactin secretion than classi cal neuroleptics. Recently, it was shown that remoxipride blocks D2 as well as D3 receptors as well as the sigma opioid receptor. Rem oxipiride has been shown to antagonize am phetam ine induced hyper locomotor activity and dem onstrate few er stereoty pic behaviors. The significance of these two effects is not yet very clear.
Klinik Psikofarm akoloji B ü lten i / Cilt 8: Sayı 3, 1 9 9 8 Nine m ulticentre controlled double blind studi es com pared rem oxipride efficacy with haloperidol in treating acute schizophrenia. In a Canadian study (12) 242 schizophrenic patients and 242 patients pre senting acute schizophrenia were treated with three dosages of rem oxipride compared to placebo. In a range of 20 to 600 m g /d ay , remoxipride was com parable in efficacy with haloperidol used in a dose ranging from 15 to 45 m g/d ay . Remoxipride treated patients had better improvement of their negative symptoms as well as presenting with less extrapyramidal and neuroendocrinological side effects com pared with haloperidol treated patients. On the ot her hand, more patients exhibited akathisia in the remoxipride group. Tardive dyskinesia risk seems to be less likely to develop with remoxipride com pared to haloperidol. Eight cases of aplastic anemia out of 45000 rem oxipride treated patients resulted in the withdrawal of remoxipride from the Swiss market which lead to withdraw..
Agonists of D2 presynaptic receptors
These m olecules, B-HT 920, EMD 49980, SND 919 and roxindole seem to decrease prolactinemia without inducing catalepsia. The actual evidence is poor and not conclusive (7). 
D4 antagonists
Distribution of mRNA that code for synthesis of D4 receptors shows that it is mainly located in the limbic and m esocortical areas. Blockade of this re ceptor could explain the better activity of clozapine and olanzapine in refractory schizophrenia. Post Mortem studies have shown that there was a high density of this receptor in schizophrenic patients. However, it has been found that recently, there is no link between D4 receptor density and treatment res ponse, and that it is not a predisposing factor of the illness (14) .
Antipsychotic drugs with selective serotoninergic antagonism
Interest in the serotoninergic system is incre asing in recent years because there is evidence that it plays a role in depression, anxiety and more re cently in schizophrenia (15).
5-HT2 receptor blockers
It is known that thioridazine, clozapine and so me other neuroleptics act as 5-HT2 antagonists besi de their activities on the dopam inergic system. Re cently 5-HT2 selective antagonists have been deve loped. Ritanserin is the most representative of these compounds. This drug wras widely studied. It incre ases the activity of the dopam inergic neurons loca ted in the mid-brain. This stim ulating effect leads to the idea that 5-HT2 receptor blockers could im pro ve negative symptoms in schizophrenia. However, there are few clinical trials of the antipsychotic acti vity of this compound.
5-HT3 blockers
Animal studies lead to evidence that 5-HT3 an tagonists can reduce hyperactivity induced by do paminergic agonists when directly injected in lim bic structures. It was proven in open clinical trials that ondansetron which is a 5-HT3 selective blocker, had some antipsychotic properties at low but not at high doses. Several short term double blind studies confirmed some antipsychotic properties of the drug. Yet, the development of ondansetron in schi zophrenia was kept aside in favor of other 5-HT3 blockers such granisetron, GR 68 756 C and BRL 46-470. Clinical studies of these com pounds are pro moted and evidence is waited upon to know if the se kind of drugs have any efficacy in treatment of schizophrenia.
Antipsychotics with simultaneous blockade of D2 and 5-H T2 receptors :
Serotonergic neurons projecting from the raphe nuclei, have an inhibitory effect upon dopaminergic transmission inside the nigro-striatal and mesocor-C> tical areas leading to decreases in dopamine synthe sis and release. In schizophrenic patients, this dopa mine inhibition would be exasperated, and mav Risperidone is a benzisoxazole derivative with 5-HT2 antagonist properties as well as D2 antagonism. Several double blind controlled studies using haloperidol (20 m g/day) and placebo in chronic schi zophrenics (16, 17, 18) showed that risperidone is a potent antipsychotic drug with an optimal efficacy in a range of 4 to 8 m g /d a y upon negative symptoms. Meta-analysis showed a better activity of risperidone upon negative symptoms comparative with haloperidol. Furthermore, risperidone induced few extrapyramidal effects. Some patients showed such effects as well as an increase of prolactin. Clini cal trials comparing risperidone with clozapine, perphenezine and zuclopenthixol have not shown significant differences in their respective efficacy. On the other hand, efficacy of risperidone on refrac tory schizophrenia has not yet been demonstrated.
Alpha-adreno receptor blockers
Risperidone is also shown to exert blocking ef fects on alpha 1 and alpha 2-adreno receptors. The noradrenergic hypothesis in antipsychotic effect emerged ten years ago as a research pathway, but it was not possible to demonstrate that hypernoradrenergic activity increased in schizophrenic patients to exclude it. Numerous neuroleptics possess alpha 1 adreno-receptor blocking effects. This property le ads to a sedative effect, orthostatic hypotension, tachycardia and vertigo and could potentiate an an tihypertensive treatment. It is not known what are the clinical consequences of risperidone alpha 2 adreno-receptors blockade.
Seroquel exhibits an alpha 1 adreno-receptor blockade higher than its blockade of D2 and 5-HT2 receptors. The only study yet published is a com pa rative study with chlorpromazine (385 m g/day). In that study using BPRS, CGI and PANSS, seroquel (400 m g /d ay ) has not shown any superiority com pared with chlorpromazine. In that clinical, trial extrapyram idal effects were not different in the three groups i.e. seroquel, chlorpromazine and pla cebo, leading to the idea of some bias. The main si de effects observed with risperidone were sedation, dry mouth and orthostatic hypotension (19) .
ANTIPSYCHOTICS WITH ANTAGONISM OF NUMEROUS RECEPTORS, THE SO CALLED MIXED ANTIPSYCHOTICS
Active neuroleptics on refractory schizophrenia have antagonizing activity of numerous receptors: dopam inergic, alpha-adrenergic, m uscarinic and histaminergic (HI). The ratio 5-HT2/ D 2 is greater than 1 and dopaminergic binding is more im portant at limbic and mesocortical Dj and D4 receptor le vels. The first drug showing this profile was cloza pine but now olanzapine has a similar one.
Clozapine was developed in the beginning of the sixties as a derivative of the dibenzodiazepine family. It wras shown that clozapine had antipsycho tic properties equal or higher than neuroleptics used at that period but with few extra-pyram idal symptoms and no hyperprolactinem ia (20) . Cloza pine does not induce tardive dyskinesia and could be active on tardive dyskinesia induced by classical neuroleptics. At the beginning of 1970's, clinical tri als with clozapine w7ere stopped in N orth America because it induced agranulocytosis. Clinical interest of clozapine was recovered because of its proved ef ficacy on refractory schizophrenia (around 30% of this kind of patients were improved). Recently, clo zapine was registered in Europe than in North America with restrictive conditions because of its hematological toxicity and particularly agranulocy tosis found in at least 0.8% of treated patients. So the only use now is in the treatment of refractory schi zophrenia with a strict monitoring of the hem atolo gical parameters. Beside its efficacy in refractory schizophrenia, clozapine is interesting concerning its pharmacological profile which seems to be w i der than that of classical neuroleptics. It is claimed to have an efficacy on cognitive defect, im prove ment of attention verbal fluency and recall memory of schizophrenics. On the other hand, it improves cognitive disorder in Parkinson disease. The major side effects of clozapine are hypersialorrhea (33% of patients), weight gain as well as convulsions which are dose-dependent (1 to 4,4% ) (21) .
Olanzapine is a new antipsychotic drug with a close psychopharmacological profile with clozapi ne. Its efficacy wras shown to be better than halope ridol as well as on positive and negative symptoms. Clinical trials have shown that olanzapine had bet ter eificacy than haloperidol and risperidone on depressive symptoms and suicidal ideas. It induces a better improvement of quality of life, already sig nificant after some months of treatment. A potential anxiolytic effect of olanzapine is discussed because of the weak consumption of benzodiazepines, less drop out linked to anxiety in the olanzapine group Klinik Psikofarm akoloji B ü lten i / C ilt 8: Sayı 3, 1 9 9 8 (22) . Tolerance is good with few extra-pyramidal ef fects, no agranulocytosis and no tardive dyskinesia (23) . It is too early to say if olanzapine could have an efficacy in patients refractory to clozapine treatment and if it could treat tardive dyskinesia.
Histam inergic Hj-receptor blockers
Clozapine and olanzapine block central histami nergic receptors inducing sedative effects as well as an orexigenic effect with an increase in weight (24) .
Cholinergic receptor blockers
Cholinergic receptors are implicated in motor activity as well as in am nesic processes. It is not known at the m oment if there is any relationship between clozapine and olanzapine blockade of cho linergic receptors and their superiority of action on negative symptoms. Long term treatment by neuro leptics induced an hypersensitivity of dopaminergic receptors and down-regulation of the cholinergic. Their im plication in tardive dyskinesia is not clear as well as the anticholinergic effect to prevent them. On the other hand, blockade of cholinergic recep tors decreased the extrapyramidal side effects but induced parasym patholytic side effects.
AM INOACID RECEPTOR BLOCKERS
Developments in this field are based on the fact that phencyclidine which is N-methyl-D-aspartate (NMDA) receptor blocker, induced psychotic featu res in healthy volunteers. Furthermore, glutamate is known to inhibit dopam inergic subcortical activity. These matters of evidence are linked to the fact that glutaminergic deficit could be implicated in pat hophysiology of schizophrenia, corticolimbic ne uronal neurodegeneration. Unfortunately, the first studies using glycine and micelamide gave negative results. On the other hand, it was proven in animals that clozapine, olanzapine and fluperlapine could prevent neurodegeneration observed when NMDA receptor activity was blocked.
SIGMA RECEPTOR ANTAGONISTS
Sigma receptors are mainly located in sub limbic area? The function of these receptors is not yet clari fied but it is thought they could modulate some do paminergic functions. Several neuroleptics, inclu ding haloperidol and remoxipride, bind to sigma re ceptors, but there is no evidence of any clinical fe ature. Recently studied sigma receptor antagonists such a rimcazole, cinuperone, BMY 14802 and BW 234 have shown very contradictory results.
CCK-B AND CCK-A RECEPTORS ANTAGONISTS
The relationship between cholecystokinin (CCK) and schizophrenia was the m atter of numerous ar ticles (for review see 25) and still is under research.
CCK-B receptors are linked with m esolimbic and nigrostriatal dopam inergic pathways, they mo dulate dopaminergic function (26) . It was shown that acute and chronic adm inistration of a selective CCK-B receptor blocker (LY 262691) decreases midbrain dopam inergic cells activity (27) . The re sults are in favor that CCK-B antagonists could ha ve an antipsychotic effect by m odulating dopam i nergic release. The effect seems to be more physiolo gical than blockade of dopam inergic receptors (28) . This regulation could avoid the long term side ef fects of neuroleptics such as tardive dyskinesia.
CONCLUSION
The research on antipsychotic drugs with more efficacy and tolerance was an important subject du ring the last years (29) . Num erous drugs were stu died. Some of them could be new treatment strate gies compared with the classical dopam inergic an tagonism. The limbic and frontal cortex specificity leads to a better tolerance as well as a better efficacy on negative symptoms with better quality of life for patients and at the end a decrease of the burden of schizophrenia. It was shown that new antipsychotic drugs decreased by 10% rehospitalisation of respon ders or non-responders (22) . The profile of the new drugs leads to a better dopam inergic balance and decreases in spontaneous instability, and negative symptoms as wrell as limiting fluctuations between positive and negative symptoms. They seem to act as psychic stabilizers (30) .
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